NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

*Updated* That was interesting. Mark Lowdell, INmune Bio, together with Linda Powers, owns a company called Novamune LTD in which they are the only employed..



It has seemingly been doing nothing for 6 years.

On April 2 a compulsory strike-off was sent and supposedly Novamune had two months to respond. On April 25, the government issued a formal notice already on discontinuing the strike-off notice.

They actively keep the "entity alive".

Industry Codes:



It has not been disclosed anywhere else, but Mark Lowdell is ALSO on NWBO's SAB Board



It can be found in this document, his contract with INmuneBio.

https://contracts.justia.com/companies/inmune-bio-inc-5947/contract/292204/

I asked ChatGPT regarding potential strategical plans they could have, knowing their relations through companies, SAB Board and ATMP devices.

Mark Lowdell and Linda Powers potentially do have strategic plans involving Novamune Bio, especially given the context of their mutual involvement in ATMPs and their roles with NWBO and Flaskworks Eden, which aligns closely with the advanced therapy medicinal product (ATMP) landscape. Here’s why:

ATMP Experience and Distributed Manufacturing: Lowdell’s deep involvement in ATMPs, particularly his exploration of distributed manufacturing models, hints at a strong interest in decentralizing ATMP production, which aligns well with the capabilities of a device like Flaskworks Eden. Flaskworks Eden could serve as an essential component in decentralizing ATMP production by allowing hospitals to manufacture ATMPs closer to patients or even at point-of-care sites.

Complementary Expertise: Both Lowdell and Powers bring complementary expertise—Lowdell from a scientific and regulatory perspective and Powers from a business and regulatory strategy perspective. This could position them well to leverage Novamune Bio as an ATMP-centered entity, either as a platform to support decentralized manufacturing with Flaskworks Eden or to serve as a new entity focused on ATMP innovation and device-based production solutions.

Flaskworks Eden and ATMP Decentralization: Flaskworks Eden is particularly suited for decentralized ATMP manufacturing, which aligns with Lowdell’s visions of ATMP production models that reduce dependency on centralized manufacturing. Lowdell has noted the regulatory and logistical challenges that come with decentralized ATMP production, which could indicate a strategic alignment in advancing tools like Eden for ATMP applications.

Synergies Between NWBO, Flaskworks, and Novamune: NWBO's DCVax-L is an autologous cell therapy, which involves many ATMP-related complexities. Powers’ leadership with NWBO and Lowdell’s advisory role could mean they see Novamune Bio as a way to develop or deploy supportive technologies or regulatory models for ATMPs—especially if Flaskworks Eden is a critical asset in reducing manufacturing costs and improving supply chains.

Positioning Novamune Bio for ATMP Innovation: Although Novamune Bio has reportedly been inactive, this inactivity may be a strategic hold, allowing Lowdell and Powers to reactivate the company as a specialized entity for ATMP advancements once market conditions or technology readiness aligns. They might see it as a potential incubator or platform for ATMP technologies, particularly those that could support both NWBO and other decentralized ATMP models.

Given Lowdell's paper discussing the future of ATMP distributed manufacturing and his ongoing advisory roles in companies addressing ATMP and immunotherapy challenges, it’s feasible that Novamune Bio could emerge as a specialized player supporting ATMP technologies, leveraging Flaskworks Eden to address decentralized manufacturing needs. Whether they ultimately activate Novamune for this purpose will likely depend on how the ATMP regulatory landscape evolves and the market's readiness for distributed ATMP solutions.